Weight loss at a high cost: Orlistat-induced late-onset severe kidney disease.
Diabetes Metab
; 42(1): 62-4, 2016 Feb.
Article
de En
| MEDLINE
| ID: mdl-26454353
ABSTRACT
AIM:
This report describes a case of kidney failure secondary to orlistat, a lipase inhibitor commonly used in the treatment of obesity. CASE REPORT An 80-year-old man with type 2 diabetes who was being treated with orlistat developed rapidly progressive kidney failure. Low-grade albuminuria argued against diabetic nephropathy. Renal biopsy showed tubulointerstitial nephritis associated with numerous calcium oxalate crystals. Enteric hyperoxaluria was attributed to the orlistat treatment. The latter was stopped and the patient received calcium supplements. Six months after orlistat withdrawal, oxaluria was normalized and kidney function stabilized.CONCLUSION:
Oxalate nephropathy may result from hyperoxaluria secondary to orlistat treatment. This suggests that kidney function and oxaluria be closely monitored in patients taking orlistat.Mots clés
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Agents antiobésité
/
Diabète de type 2
/
Maladies du rein
/
Lactones
Type d'étude:
Health_economic_evaluation
Aspects:
Patient_preference
Limites:
Aged80
/
Humans
/
Male
Langue:
En
Journal:
Diabetes Metab
Sujet du journal:
ENDOCRINOLOGIA
/
METABOLISMO
Année:
2016
Type de document:
Article
Pays d'affiliation:
Belgique